$8.29
+0.18(2.28%)
Mkt Cap $824M
$6.73
$18.35
52-Week Range
At a Glance
AI-generatedARS Pharmaceuticals, Inc.
8-K
ARS Pharmaceuticals, Inc. announced fourth quarter and full year 2025 financial results, reporting $28.1 million total revenue including $20.3 million U.S. neffy net product revenue and $72.2 million full year U.S. neffy net product revenue, with $245.0 million in cash supporting operations through cash-flow break-even. The company updated its corporate presentation and provided neffy commercialization and regulatory updates.$824M
Market Cap
$85M
Revenue
-$173M
Net Income
Employees155
Fundamentals
How The Business Makes Money
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001671858
ISINUS82835W1080
CUSIP82835W108
Phone858 335 1300
Address3525 Del Mar Heights Road, San Diego, CA, 92130, US
SEC EDGAR